Despite effectiveness and safety issues, a vaccine targeting Respiratory Syncytial Virus (RSV) by GlaxoSmithKline Biologicals (GSK) was approved by the FDA on May 3, 2023 for people ages 60 and older, and now Pfizer’s RSV vaccine targeting pregnant women is moving through the perfunctory steps of captured federal agencies on it’s way to licensing. Listen to …
Time to celebrate! In this long journey to restore freedom and instill scientific integrity in public policies, it’s important to pause and enjoy each victory. While we celebrate, we also somberly acknowledge those harmed by the government policies represented by these announcements. When products and policies harm, we must all work to end their use …
Wow! Two studies and one court decision to celebrate! Read More »
Children and teen vaccination rates began plummeting with the onset of the pandemic, and as concerns surfaced around the safety of COVID-19 vaccines, some parents also began questioning the need for the long list of other vaccines recommended by public health officials. By The Defender Staff © August 12, 2022 Children’s Health Defense, Inc. This work …
A COVID Silver Lining? More Parents Than Ever Questioning ‘Routine’ Childhood Vaccines Read More »
